Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
LONDON (Reuters) - U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds ($106 billion) on Friday, but the British company promptly rejected the proposal, which would ...
Pfizer ($PFE) appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its ...
AstraZeneca PLC announced a deal with President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc. “Today, ...
Zacks Investment Research on MSN
Pfizer bets on new & acquired drugs to offset its LOE pressure?
Pfizer PFE is facing one of the steepest patent cliffs in the large-cap pharma space. The company expects a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results